2nd Quarter - Report

JAZZ PHARMACEUTICALS, INC. for JAZZ PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$520,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

S.2860 - SAFER Banking Act HR 5539/ S. 3131 - Orphan Cures Act HR 8467 - Farm, Food, and National Security Act of 2024 Hemp definition Changes to Inflation Reduction Act Drug safety, prescription drug abuse, value of prescription drugs Issues related to the regulation of cannabis and CBD Research and development of cannabis-derived therapies

LobbyistCovered position, as disclosed
MARK BOLTON —
KARAS GROSS —
VIRGINIA MCMILLIN —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2860 (118th), H.R. 8467 (118th), S. 3131 (118th), H.R. 5539 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.